Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
This article was originally published in The Tan Sheet
Executive Summary
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.
You may also be interested in...
FDA Staying The Course Under Ostroff; Hamburg’s Concerns Remain Focus
Acting FDA Commissioner Ostroff says he does not envision new major priorities that would emerge in the short-term. The former FDA chief scientist is non-committal about submitting his name as a candidate for permanent commissioner.
FDA Staying The Course Under Ostroff; Hamburg’s Concerns Remain Focus
Acting FDA Commissioner Ostroff says he does not envision new major priorities that would emerge in the short-term. The former FDA chief scientist is non-committal about submitting his name as a candidate for permanent commissioner.
Examine Tighter Supplement Industry Regulation, Hamburg Tells Congress
FDA Commissioner Hamburg does not give a positive review of the current framework when Rep. Lowey questions oversight of the supplement industry during an appropriations hearing. Hamburg also says FDA needs more resources for regulating supplement production and marketing, including “snake oil salesmen.”